Rein Therapeutics (RNTX) Competitors $1.11 -0.08 (-6.72%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNTX vs. SKYE, PLX, TARA, SPRO, CRBP, PYXS, FATE, BMEA, PLRX, and EQShould you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Skye Bioscience (SKYE), Protalix BioTherapeutics (PLX), Protara Therapeutics (TARA), Spero Therapeutics (SPRO), Corbus Pharmaceuticals (CRBP), Pyxis Oncology (PYXS), Fate Therapeutics (FATE), Biomea Fusion (BMEA), Pliant Therapeutics (PLRX), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry. Rein Therapeutics vs. Its Competitors Skye Bioscience Protalix BioTherapeutics Protara Therapeutics Spero Therapeutics Corbus Pharmaceuticals Pyxis Oncology Fate Therapeutics Biomea Fusion Pliant Therapeutics Equillium Skye Bioscience (NASDAQ:SKYE) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations. Do insiders & institutionals believe in SKYE or RNTX? 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility and risk, SKYE or RNTX? Skye Bioscience has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Rein Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Is SKYE or RNTX more profitable? Skye Bioscience's return on equity of -76.03% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -76.03% -69.20% Rein Therapeutics N/A -141.11%-33.83% Does the media prefer SKYE or RNTX? In the previous week, Skye Bioscience had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Skye Bioscience and 2 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.32 beat Skye Bioscience's score of 0.70 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate SKYE or RNTX? Skye Bioscience currently has a consensus target price of $15.50, suggesting a potential upside of 280.84%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Rein Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation and earnings, SKYE or RNTX? Skye Bioscience is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$26.57M-$1.06-3.84Rein TherapeuticsN/AN/A-$62.88M-$2.69-0.41 SummarySkye Bioscience beats Rein Therapeutics on 9 of the 14 factors compared between the two stocks. Get Rein Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNTX vs. The Competition Export to ExcelMetricRein TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.87M$3.10B$5.74B$10.24BDividend YieldN/A2.32%5.69%4.59%P/E Ratio-0.4121.3874.9326.41Price / SalesN/A244.04457.2789.16Price / Cash2.6644.4425.8129.91Price / Book2.589.6413.256.28Net Income-$62.88M-$53.20M$3.29B$270.38M7 Day Performance-17.16%0.44%0.47%2.70%1 Month Performance-7.04%4.26%4.60%5.99%1 Year PerformanceN/A9.43%73.42%25.94% Rein Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNTXRein Therapeutics0.9868 of 5 stars$1.11-6.7%N/AN/A$25.87MN/A-0.419Gap DownSKYESkye Bioscience2.0613 of 5 stars$4.00+6.7%$15.50+287.5%-29.2%$123.95MN/A-3.7711Gap UpHigh Trading VolumePLXProtalix BioTherapeutics2.3323 of 5 stars$1.54-3.1%$15.00+874.0%+72.4%$122.79M$61.95M-11.85200TARAProtara Therapeutics1.7398 of 5 stars$3.15-0.6%$19.60+522.2%+67.0%$121.53MN/A-1.9430Positive NewsSPROSpero Therapeutics4.3881 of 5 stars$2.15+0.5%$5.00+132.6%+38.7%$120.99M$47.98M-2.19150News CoveragePositive NewsShort Interest ↓CRBPCorbus Pharmaceuticals4.3171 of 5 stars$9.86-1.6%$49.00+397.0%-83.0%$120.83MN/A-2.0740Positive NewsPYXSPyxis Oncology2.6957 of 5 stars$1.91+18.6%$7.75+305.8%-51.9%$118.45M$16.15M-1.1960High Trading VolumeFATEFate Therapeutics3.9732 of 5 stars$1.01+3.8%$3.30+226.7%-76.0%$116.48M$13.63M-0.70550Positive NewsBMEABiomea Fusion3.4256 of 5 stars$1.92+4.9%$14.80+670.8%-75.4%$114.26MN/A-0.6350Positive NewsPLRXPliant Therapeutics4.1099 of 5 stars$1.86+14.1%$8.19+340.2%-86.8%$114.18M$1.58M-0.5590Positive NewsGap UpHigh Trading VolumeEQEquillium0.7641 of 5 stars$1.91+9.1%$1.00-47.6%+114.9%$113.65M$41.10M-3.4140Short Interest ↓Gap Down Related Companies and Tools Related Companies SKYE Competitors PLX Competitors TARA Competitors SPRO Competitors CRBP Competitors PYXS Competitors FATE Competitors BMEA Competitors PLRX Competitors EQ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNTX) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rein Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rein Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNTX Stock Alerts